Mode
Text Size
Log in / Sign up
N/A Completed N=299

Drug Outcome Survey for Biological Treatments in Rheumatoid Arthritis: an Observational Study (Dose)

Source: ClinicalTrials.gov NCT00794118 ↗
Enrolled (actual)
299
Serious AEs
0.0%
Results posted
May 2012
Primary outcomePrimary: Percentage of Participants With Disease Activity Score Based on 28-joints Count (DAS28) Remission at Month 3 — 13.4 Percentage of participants

Summary

The primary purpose of this observational study is to describe and define the current daily practice of management of anti-TNF-agents in Rheumatoid Arthritis (RA) patients. Data will be collected only from subjects providing informed consent.

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants With Disease Activity Score Based on 28-joints Count (DAS28) Remission at Month 3
13.4 —
PRIMARY
Percentage of Participants With Disease Activity Score Based on 28-joints Count (DAS28) Remission at Month 6
21.6 —
PRIMARY
Percentage of Participants With Disease Activity Score Based on 28-joints Count (DAS28) Remission at Month 9
27.2 —
PRIMARY
Percentage of Participants With Disease Activity Score Based on 28-joints Count (DAS28) Remission at Month 12
22.6 —
PRIMARY
Disease Activity Score Based on 28-joints Count (DAS28) at Month 3
4.2 —
PRIMARY
Disease Activity Score Based on 28-joints Count (DAS28) at Month 6
3.7 —
PRIMARY
Disease Activity Score Based on 28-joints Count (DAS28) at Month 9
3.4 —
PRIMARY
Disease Activity Score Based on 28-joints Count (DAS28) at Month 12
3.6 —
PRIMARY
Patient Global Assessment (PtGA) of Disease Activity Score at Month 3
4.1 —
PRIMARY
Patient Global Assessment (PtGA) of Disease Activity Score at Month 6
3.4 —
PRIMARY
Patient Global Assessment (PtGA) of Disease Activity Score at Month 9
2.8 —
PRIMARY
Patient Global Assessment (PtGA) of Disease Activity Score at Month 12
3.3 —
PRIMARY
Physician Global Assessment (PGA) of Disease Activity at Month 3
3.7 —
PRIMARY
Physician Global Assessment (PGA) of Disease Activity at Month 6
2.9 —
PRIMARY
Physician Global Assessment (PGA) of Disease Activity at Month 9
2.3 —
PRIMARY
Physician Global Assessment (PGA) of Disease Activity at Month 12
2.8 —
PRIMARY
Visual Analogue Scale for Pain (VAS-pain) at Month 3
4.1 —
PRIMARY
Visual Analogue Scale for Pain (VAS-pain) at Month 6
3.3 —
PRIMARY
Visual Analogue Scale for Pain (VAS-pain) at Month 9
2.9 —
PRIMARY
Visual Analogue Scale for Pain (VAS-pain) at Month 12
3.3 —
PRIMARY
C-reactive Protein (CRP) at Month 3
1.4 —
PRIMARY
C-reactive Protein (CRP) at Month 6
1.3 —
PRIMARY
C-reactive Protein (CRP) at Month 9
1.1 —
PRIMARY
C-reactive Protein (CRP) at Month 12
1.5 —
PRIMARY
Erythrocyte Sedimentation Rate (ESR) at Month 3
23.9 —
PRIMARY
Erythrocyte Sedimentation Rate (ESR) at Month 6
20.8 —
PRIMARY
Erythrocyte Sedimentation Rate (ESR) at Month 9
18.4 —
PRIMARY
Erythrocyte Sedimentation Rate (ESR) at Month 12
21.9 —
PRIMARY
Number of Participants With Rheumatoid Factor (RF) at Month 3
80; 88; 98 —
PRIMARY
Number of Participants With Rheumatoid Factor (RF) at Month 6
77; 74; 83 —
PRIMARY
Number of Participants With Rheumatoid Factor (RF) at Month 9
63; 57; 106 —
PRIMARY
Number of Participants With Rheumatoid Factor (RF) at Month 12
88; 67; 117 —
PRIMARY
Number of Participants With Anti-cyclic Citrullinated Protein (Anti-CCP) Antibodies at Month 3
43; 50; 174 —
PRIMARY
Number of Participants With Anti-cyclic Citrullinated Protein (Anti-CCP) Antibodies at Month 6
44; 44; 147 —
PRIMARY
Number of Participants With Anti-cyclic Citrullinated Protein (Anti-CCP) Antibodies at Month 9
32; 39; 154 —
PRIMARY
Number of Participants With Anti-cyclic Citrullinated Protein (Anti-CCP) Antibodies at Month 12
52; 45; 175 —
PRIMARY
Number of Participants With Anti-nuclear Antibodies at Month 3
8; 78; 181 —
PRIMARY
Number of Participants With Anti-nuclear Antibodies at Month 6
14; 79; 142 —
PRIMARY
Number of Participants With Anti-nuclear Antibodies at Month 9
9; 57; 159 —
PRIMARY
Number of Participants With Anti-nuclear Antibodies at Month 12
14; 85; 173 —
PRIMARY
Number of Participants With Anti-deoxyribonucleic Acid (Anti-DNA) Antibodies at Month 3
1; 79; 187 —
PRIMARY
Number of Participants With Anti-deoxyribonucleic Acid (Anti-DNA) Antibodies at Month 6
1; 80; 154 —
PRIMARY
Number of Participants With Anti-deoxyribonucleic Acid (Anti-DNA) Antibodies at Month 9
4; 60; 161 —
PRIMARY
Number of Participants With Anti-deoxyribonucleic Acid (Anti-DNA) Antibodies at Month 12
3; 88; 181 —
PRIMARY
Duration of Morning Stiffness at Month 3
26.4 —
PRIMARY
Duration of Morning Stiffness at Month 6
19.6 —
PRIMARY
Duration of Morning Stiffness at Month 9
13.2 —
PRIMARY
Duration of Morning Stiffness at Month 12
17.8 —
PRIMARY
Stanford Health Assessment Questionnaire (HAQ) Score at Month 3
1.0 —
PRIMARY
Stanford Health Assessment Questionnaire (HAQ) Score at Month 6
0.7 —
PRIMARY
Stanford Health Assessment Questionnaire (HAQ) Score at Month 9
0.7 —
PRIMARY
Stanford Health Assessment Questionnaire (HAQ) Score at Month 12
0.8 —
PRIMARY
36-Item Short-Form Health Survey (SF-36) at Month 12
52.2; 55.5 —
SECONDARY
Direct Costs
— —
SECONDARY
Indirect Costs
— —

Eligibility Criteria

Inclusion Criteria

  • Eighteen years of age or older
  • Diagnosis of RA in accordance with ARA 1987 classification has satisfied at least 4 of the following 7 criteria:
  • Morning stiffness in and around the joints lasting at least 1 hour;
  • Arthritis of 3 or more joint areas;
  • Arthritis of hand joints;
  • Symmetric arthritis. simultaneous involvement of the same joint areas on both sides of the body;
  • Rheumatoid nodules;
  • Serum Rheumatoid Factor (RF)
  • Radiographic changes. Criteria 1 through 4 must have been present for at least 6 weeks.
  • Patients refractory or without complete response to DMARDs according to the Italian Guidelines for the clinical practice established by Italian Society of Rheumatology
  • Patients naive to anti-TNF drugs
  • Outpatients

Exclusion Criteria

Patients involved in controlled or interventional trials in the 12 previous months

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00794118). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search